Investor Announcements - 2012

Interim results

24^th Sep 2012

EKF announces 2012 Interim Results.

HemoCue settlement agreement

10^th Aug 2012

EKF Diagnostics announces that subsidiaries of EKF have entered into a Settlement Agreement with HemoCue AB and HemoCue Inc in relation to patent-related litigation in Germany and the US.

Licensing Agreement for Kidney Markers

17^th Jul 2012

EKF Diagnostics announces that it has signed an exclusive license agreement with the Joslin Diabetes Center (“Joslin”).

Disposal of International Brand Licensing AG

27^th Mar 2012

EKF Diagnostics announces that it has sold its Swiss subsidiary, International Brand Licensing AG for a cash consideration of £50,000, payable over a two year period.

Final results for the year ended 31 December 2011

21^st Mar 2012

EKF Diagnostics announces its audited final results for the year ended 31 December 2011, a year of continued progress.

Archive

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

AIM Awards 2019

EKF Diagnostics was delighted to win the AIM Transaction of the Year Award at the AIM Awards 2019.

New R&D facility in Head Office

Special Projects Laboratory opened in EKF’s Cardiff HQ to develop new applications in non-core markets and support other global diagnostics R&D facilities

Medica 2019

Medica is the world’s largest medical trade fair. For more than 40 years it has been firmly established on every professional's calendar attracting over 40,000 delegates and over 5,000 exhibitors from 70 countries in 17 halls.

EKF to highlight Lucica® Glycated Albumin-L assay for diabetes patient monitoring at AACC 2019

EKF announces the availability of a liquid, enzymatic test for glycated albumin (GA) that was recently FDA cleared for sales in the U.S. GA, used for intermediate term monitoring of glycemic control in diabetes patients, will be showcased at the 2019 AACC.

EKF at InterLab - Algiers, Algeria 2019

The third edition of the exhibition will be held on 25-27 September 2019 at the Palais des Expositions, SAFEX, Algiers, Algeria.